Angiotech Pharmaceuticals, Inc.
Angiotech Pharmaceuticals is teaching old devices new tricks. The firm develops medical products that combine devices with drugs to make them more effective with fewer side effects. Its flagship product in the Pharmaceutical Technologies segment is the TAXUS drug-eluting stent, which Boston Scientific sells and for which it pays Angiotech royalties. The stent is used to open up diseased arteries, and the drug coating keeps scar tissue from forming and creating a new blockage. The company's Medical Products segment makes the Quill wound closure system and other single-use medical products for interventional radiology, ophthalmology, and surgery. Angiotech has facilities in North America and Europe.
Contact Details
Executives
Chairman
David T. Howard
President, CEO, and Director
William L. Hunter